ONYX LABS

# CJC-1295 + Ipamorelin Blend

## QUALITY CONTROL CERTIFICATE

CJC-1295 + Ipamorelin acetate blend

**Certificate No.**
CP-QCC-2026-055952

**Lot Number**
CJCIPM-MAY26-6L3ONX

**Release Date**
2026.05.20

### PRODUCT INFORMATION

| | |
|---|---|
| Product Name | CJC-1295 + Ipamorelin Blend |
| Dosage Form | Lyophilized powder (reconstitute before use) |
| Total Peptide Content | 10 mg per vial (CJC-1295: 5 mg + Ipamorelin: 5 mg) |
| Appearance | White to off-white lyophilized cake/powder |
| Solubility | Freely soluble in bacteriostatic water or sterile water |
| Storage | Refrigerate 2-8 C; protect from light |
| Intended Use | Laboratory research use only - not for human consumption |

### COMPOSITION REFERENCE

CJC-1295 with DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-DAC

Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

*Peptide sequence records for identity verification purposes*

### QUALITY CONTROL TEST RESULTS

| Test | Method | Specification | Result | Status |
|---|---|---|---|---|
| Appearance | Visual | White lyophilized cake | Conforms | PASS |
| Identity (CJC-1295) | HPLC/MS | Matches reference | Confirmed | PASS |
| Identity (Ipamorelin) | HPLC/MS | Matches reference | Confirmed | PASS |
| Purity (CJC-1295) | HPLC | >= 98.0% | 99.1% | PASS |
| Purity (Ipamorelin) | HPLC | >= 98.0% | 98.7% | PASS |
| Peptide Content | Gravimetric | Report result | 12.04 mg | PASS |
| Endotoxin | USP <85> LAL | < 0.50 EU/mg | < 0.10 EU/mg | PASS |
| Sterility | USP <71> | No growth (14 days) | No growth | PASS |

### CERTIFICATION

This product has been manufactured, tested, and released in accordance with national quality standards. All tests performed meet or exceed applicable specifications.

**RELEASED FOR DISTRIBUTION • LOT: CJCIPM-MAY26-6L3ONX • RELEASE DATE: 2026.05.20**

ONYX LABS

# Tirzepatide

## QUALITY CONTROL CERTIFICATE

Tirzepatide (GIP/GLP-1 Dual Receptor Agonist)

**Certificate No.**
CP-QCC-2026-052639

**Lot Number**
TZ-MAY26-3V9ONX

**Release Date**
2026.05.27

### PRODUCT INFORMATION

| | |
|---|---|
| Product Name | Tirzepatide |
| Dosage Form | Lyophilized powder (reconstitute before use) |
| Peptide Content | 10 mg per vial |
| Appearance | White to off-white lyophilized powder |
| Solubility | Freely soluble in sterile water or bacteriostatic water |
| Storage | Refrigerate 2-8 C; protect from light and moisture |
| Intended Use | Laboratory research use only - not for human consumption |

### COMPOSITION REFERENCE

Y-Aib-E-G-T-F-T-S-D-Y-S-I-Aib-L-D-K-I-A-Q-K(γE-AEEA-AEEA-C20diacid)-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2

*39-mer GIP/GLP-1 dual agonist; C20 fatty diacid at K20 via gE-AEEA-AEEA linker; C-terminal amide; confirmed by LC-MS*

### QUALITY CONTROL TEST RESULTS

| Test | Method | Specification | Result | Status |
|---|---|---|---|---|
| Appearance | Visual | White lyophilized powder | Conforms | PASS |
| Identity | HPLC/MS | Matches reference | Confirmed | PASS |
| Purity | HPLC | >= 98.0% | 99.2% | PASS |
| Peptide Content | Gravimetric | Report result | 10.1 mg | PASS |
| Related Substances | HPLC | <= 2.0% | 0.8% | PASS |
| Endotoxin | USP <85> LAL | < 0.50 EU/mg | < 0.10 EU/mg | PASS |
| Sterility | USP <71> | No growth (14 days) | No growth | PASS |

### CERTIFICATION

This product has been manufactured, tested, and released in accordance with national quality standards. All tests performed meet or exceed applicable specifications.

**RELEASED FOR DISTRIBUTION • LOT: TZ-MAY26-3V9ONX • RELEASE DATE: 2026.05.27**